Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.1% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price fell 7.1% during trading on Monday . The stock traded as low as $24.12 and last traded at $24.5730. Approximately 673,841 shares changed hands during trading, a decline of 46% from the average session volume of 1,238,818 shares. The stock had previously closed at $26.44.

Analyst Ratings Changes

Several brokerages have issued reports on CAPR. Piper Sandler reissued an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a report on Thursday. B. Riley Financial upped their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.30.

Capricor Therapeutics Price Performance

The stock’s 50-day moving average price is $30.00 and its 200 day moving average price is $28.41. The firm has a market capitalization of $1.38 billion, a PE ratio of -10.22 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities research analysts forecast that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Karimah Es Sabar sold 61,265 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 173,429 shares of company stock worth $5,329,440. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its holdings in Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after buying an additional 557 shares during the period. KBC Group NV bought a new position in shares of Capricor Therapeutics in the 1st quarter worth $44,000. ACT Capital Management LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth $43,000. Nuveen LLC lifted its stake in shares of Capricor Therapeutics by 2.1% during the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 1,878 shares during the last quarter. Finally, State of Wyoming lifted its stake in shares of Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.